Search Results - "Medori, R"

Serum IL-17F does not predict poor response to IM IFN beta -1a in relapsing-remitting MS by Bushnell, SE, Zhao, Z, Stebbins, C C, Cadavid, D, Buko, A M, Whalley, E T, Davis, JA, Versage, E M, Richert, J R, Axtell, R C, Steinman, L, Medori, R

“…Objective: There is a significant unmet need for serum biomarkers in relapsing-remitting multiple sclerosis (RRMS) that are predictive of therapeutic response…”
Get full text

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS by BUSHNELL, S. E, ZHAO, Z, STEINMAN, L, MEDORI, R, STEBBINS, C. C, CADAVID, D, BUKO, A. M, WHALLEY, E. T, DAVIS, J. A, VERSAGE, E. M, RICHERT, J. R, AXTELL, R. C

“…There is a significant unmet need for serum biomarkers in relapsing-remitting multiple sclerosis (RRMS) that are predictive of therapeutic response to…”
Get full text

A Novel mglur4 compound alleviates motor symptoms in primate models of parkinson's disease by Charvin, D., Di Paolo, T., Bezard, E., Halldin, C., Duvey, G., Gregoire, L., Takano, A., Pioli, E., Medori, R., Conquet, F.

Get full text

C.01.02 Preventing relapse in schizophrenia – what is the evidence for novel antipsychotics? by Medori, R

Get full text

A randomized controlled study of pergolide in patients with restless legs syndrome by WETTER, T. C, STIASNY, K, WINKELMANN, J, BUHLINGER, A, BRANDENBURG, U, PENZEL, T, MEDORI, R, RUBIN, M, OERTEL, W. H, TRENKWALDER, C

“…Open clinical trials indicate that low doses of pergolide, a long-acting D1 and D2 dopamine agonist, lead to a reduction in the symptoms of restless legs…”
Get full text

Direct transition to long-acting risperidone - analysis of long-term efficacy by Kissling, W., Heres, S., Lloyd, K., Sacchetti, E., Bouhours, P., Medori, R., Llorca, P. M.

“…This report presents data from the extension phase of a 6-month trial that evaluated the efficacy of risperidone long-acting injectable (RLAI) in stable…”
Get full text

Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months by Llorca, P-M, Sacchetti, E, Lloyd, K, Kissling, W, Medori, R

“…To monitor long-term symptomatic tolerability and remission in patients with stable but suboptimally treated psychoses after switching to risperidone…”
Get full text

Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia by Marinis, T De, Saleem, P T, Glue, P, Arnoldussen, W J, Teijeiro, R, Lex, A, Latif, M A, Medori, R

“…Using an atypical long-acting antipsychotic may improve patient outcome by offering the good efficacy and tolerability of an atypical antipsychotic with…”
Get more information

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable by Parellada, E., Andrezina, R., Milanova, V., Glue, P., Masiak, M., Turner, M. St. John, Medori, R., Gaebel, W.

“…The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective…”
Get full text

309 – An open-label trial of risperidone long-acting injectable by Emsley, R, Medori, R, Koen, L, Oosthuizen, P, Rabinowitz, J

Get full text

Long-acting risperidone in stable patients with schizoaffective disorder by Mohl, A., Westlye, K., Opjordsmoen, S., Lex, A., Schreiner, A., Benoit, M., Bräunig, P., Medori, R.

“…Oral and long-acting risperidone has been shown to be effective for acute and maintenance treatment of patients with schizoaffective disorders. The present…”
Get full text

Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine by Gastpar, M., Masiak, M., Latif, M. A., Frazzingaro, S., Medori, R., Lombertie, E. -R.

“…The efficacy and tolerability of risperidone long-acting injectable were investigated in patients with schizophrenia or other psychotic disorders who had…”
Get full text

270 – Concordance of patient and clinical ratings regarding symptom severity and change by Rabinowitz, J, Levine, S.Z, Medori, R, Oosthuizen, P.P, Koen, L, Emsley, R

Get full text

Long-acting risperidone improves negative symptoms in stable psychotic patients by Curtis, VA, Katsafouros, K., Möller, H-J., Medori, R., Sacchetti, E.

“…The aim of this paper was to evaluate the efficacy of risperidone long-acting injectable (RLAI) for reducing negative symptoms of schizophrenia in patients…”
Get full text

12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH by Hoare, Peter, Remschmidt, H, Medori, R, Ettrich, C, Rothenberger, A, Santosh, P, Schmit, M, Spender, Q, Tamhne, R, Thompson, M, Tinline, C, Trott, G E

“…The aim of this study was to evaluate long-term clinical treatment with OROS methylphenidate (MPH) (Concerta) in children and adolescents with…”
Get full text

Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study by Remschmidt, H, Hoare, P, Ettrich, C, Rothenberger, A, Santosh, P, Schmidt, M, Spender, Q, Tamhne, R, Thompson, M, Tinline, C, Trott, G E, Medori, R

“…The aim of this study was to assess the impact of switching from immediate-release (IR) methylphenidate (MPH) to OROS MPH (CONCERTA, a once-daily long-acting…”
Get full text

Dosing patterns in Europe: Efficacy and safety of RLAI in doses 25-50mg by Mauri, M.C, Turner, M, Volonteri, L.S, Medori, R, Maier, W

Get full text

Long-acting risperidone improves negative symptoms in stable psychotic patients by Curtis, V.A, Katsafouros, K, Moeller, H.J, Medori, R, Sacchetti, E

Get full text

Fatal familial insomnia : a second kindred with mutation of prion protein gene at codon 178 by MEDORI, R, MONTAGNA, P, TRITSCHLER, H. J, LEBLANC, A, CORTELLI, P, TINUPER, P, LUGARESI, E, GAMBETTI, P

“…Fatal familial insomnia (FFI), a condition characterized by inability to sleep, dysautonomia, motor disturbances, and selective thalamic atrophy is a prion…”
Get full text

P.8.a.016 Double-blind study of the efficacy and safety of prolonged-release methylphenidate in adults with ADHD – the LAMDA trial by Medori, R, Kooij, S, Buitelaar, J, Ramos- Quiroga, J.A, Trott, G.E, Lee, E, Casas, M

Get full text